Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00170768 |
The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
Condition | Intervention | Phase |
---|---|---|
Healthy Volunteers |
Drug: Darifenacin Drug: Oxybutynin Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over |
Enrollment: | 150 |
Study Start Date: | February 2005 |
Study Completion Date: | May 2005 |
Arms | Assigned Interventions |
---|---|
1: Experimental
Darifenacin
|
Drug: Darifenacin
Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
|
2: Active Comparator
Oxybutynin
|
Drug: Oxybutynin
Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
|
3: Placebo Comparator
Placebo
|
Drug: Placebo
Placebo once daily tablet (sham titration)
|
Ages Eligible for Study: | 60 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply.
- Current use of drugs known to effect memory and cognition Other protocol-defined inclusion/exclusion criteria may apply
United States, District of Columbia | |
Washington Neuropsychological Institute LLC Georgetown | |
washington, District of Columbia, United States, 20016 |
Study Chair: | Novartis | East Hanover NJ |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CDAR328A2403 |
Study First Received: | September 9, 2005 |
Last Updated: | January 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00170768 |
Health Authority: | United States: Food and Drug Administration |
Darifenacin, oxybutynin, cognition, memory |
Oxybutynin Darifenacin Healthy |
Muscarinic Antagonists Parasympatholytics Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists |
Autonomic Agents Physiological Effects of Drugs Peripheral Nervous System Agents Cholinergic Agents Pharmacologic Actions |